Vivjoa

oteseconazole

Approval

ApplicationNDA 215888
Approval dateApr 26, 2022
Approval year2022
SponsorMycovia Pharms

FDA-approved use

To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Vivjoa: